Burden and Trends of Crohn’s Disease Among Women of Reproductive Age in China, India, and the United States, 1990–2023, with Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study 2023 Authors: Fen Lin, Xueying Wei, Lihuan Song, Guanghui Xu, Jing Li Published: 2026 ABSTRACT PurposeCrohn’s disease (CD) represents a growing public health concern, yet comprehensive epidemiological data on women of reproductive age are limited. This study aimed to explore the incidence trends and underlying drivers of CD among women of reproductive age in China, India, and the United States (US).Patients and MethodsUsing data from the Global Burden of Disease (GBD) Study 2023, we analyzed age-standardized incidence rates (ASIR), prevalence, and disability-adjusted life years (DALYs) from 1990 to 2023. Temporal trends were assessed using the estimated annual percentage change (EAPC) and Joinpoint regression analysis. A decomposition analysis was conducted to evaluate the influencing factors, and a Bayesian Age-Period-Cohort (BAPC) model was utilized to project trends through 2040.ResultsGlobally, CD incidence among women of reproductive age showed a slow upward trend. China experienced the most rapid increase (EAPC 2.89; 95% CI: 2.23–3.55), with ASIR rising from 0.29 to 0.70/100,000. Increases were modest in India (EAPC 0.99; 95% CI: 0.79–1.18) and the US (EAPC 0.41; 95% CI: 0.22–0.61). Joinpoint regression identified varying temporal patterns across countries. Peak incidence occurred earlier in China (ages 35–39) compared to the US and India (ages 40–44). Decomposition analysis attributed China’s increasing burden primarily to epidemiological changes, whereas demographic factors drove trends in the US and India. By 2040, China’s ASIR is projected to reach 0.74/100,000, while the US rate is expected to decline. Notably, age-standardized DALY rates will decrease across all three countries, though the reduction in China was marginal compared to the US.ConclusionThe present study characterizes both distinct regional patterns of CD evolution as well as age-related changes in its course. The association with the peak period of fertility also highlights the need to have localized plans and multidisciplinary models of care. Introduction Crohn’s Disease (CD) is one of the major variants of inflammatory disease of the bowel (IBD). Its hallmark is chronic granulomatous inflammation which may extend to any part of the gastrointestinal tract.1,2 CD is a chronic incapacitating illness, which may provoke perforation, intestinal fibrosis, fistula development, and functional failure. Regardless of these tremendous improvements in pharmacological treatment and surgery, CD still remains an extremely adverse condition in terms of patients’ quality of life and incurs heavy socioeconomic expenses.3–5 It is important to note that CD is a severe problem in the field of global healthcare that disproportionately affects women of reproductive age (aged 15–49).6,7 Similarly to other diseases associated with immunity, CD demonstrates gender-dependent differences in complications and disease development:8 women with CD have higher rates of fertility loss, poor outcome in pregnancy and various gynaecological problems9,10 and common problems such as reduced quality of life, sexual disorder, increased psychological distress.8,11,12 Historical information shows that women continued to have a greater mortality rate, suffer more IBD-related disabilities and DALYs than men between 1990 and 2019; this indicates that there is a rising and gender-biased health crisis in this population.13 Nevertheless, despite an increasing number of studies on IBD burden, there are still notable gaps in current literature. Previous studies based on the Global Burden of Disease (GBD) have tended to focus on analysing IBD as an aggregate, obscuring the individual epidemic and phenotype paths of CD and ulcerative colitis. Moreover, previous studies have mostly examined the overall population, pediatric groups, or the elderly population but have not adequately explored the changing, unique burden of CD in women of reproductive age. Importantly, very few cross-national comparative studies have examined this susceptible population in areas characterized by dramatically varied healthcare systems. In response to this, we examine the burden of CD in women of reproductive age in China, India and the United States (US). The choice of the three most populous countries has an important epidemiological rationale behind it: the countries represent different phases of the epidemiological transition and different healthcare organizations. The US is a Westernised, high-income environment with a long history of high CD prevalence and sophisticated diagnostic and treatment facilities.14 In comparison, China is experiencing an accelerated epidemiological change, in which the pace of urbanisation and changes in diet are fueling a skyrocketing CD rate in a setting of uneven health care resources across regions.15 The case of India is particularly complex; the rising burden of CD coincides with extremely widespread gastrointestinal infections (including intestinal tuberculosis) which lead to considerable diagnostic delay and health care problems.16 By leveraging the latest GBD 2023 dataset which incorporates newly added health status metrics for CD, this study addresses the limitations of previous iterations by capturing post-COVID-19 temporal trends in key health metrics (prevalence, incidence, mortality, and DALYs). A transnational comparative analysis was conducted on the burden magnitude, temporal trajectories and major drivers of CD among women of reproductive age in China, India and the USA. Moreover, a predictive model was set up on the grounds of historical trend data for the purpose of forecasting the CD burden of women of reproductive age in 2040. This research scientifically underpins the development of differentiated prevention and control strategies for the above-mentioned super-populous countries. Materials and Methods Data Source In this study, data were extracted from the GBD 2023 database, officially released on October 12, 2025. Data were retrieved via the GBD Results Tool (https://vizhub.healthdata.org/gbd-results/), a public platform for global health metrics.17 Data were restricted to the world’s three most populous countries: China, India, and the United States. In line with established practices, we used open-access estimates from GBD 2023 to derive the number and rates of incident cases, prevalent cases, deaths and disability-adjusted life years (DALYs) attributable to CD. All rates were age-standardized using the global population standard (per 100000 population) and are reported as age-standardized rates (ASRs).18 ASRs reflect the underlying risk factor patterns within a specific population and aid in developing targeted prevention strategies. Additionally, all estimates were accompanied by corresponding 95% uncertainty intervals (UIs) stratified by age, location, sex, and cause.19 UIs were derived from 1000 posterior draws of the model estimates and defined as the 2.5th and 97.5th percentiles of the posterior distribution. All data were de-identified and contained no personal health information. Ethical approval and informed consent waiver for GBD 2023 were granted by the Institutional Review Board at the University of Washington. No additional ethical approval was required for this study. Study Aims and Definitions Women of reproductive age at the age of 15–49 were enrolled as the study population. They are a demographic group in line with the window of fertility recognized by the World Health Organization (WHO) and extensively applied in epidemiological studies on the reproductive health of women. The International Classification of Diseases 10th Revision (ICD-10) code K50 was used for the identification of CD.20 Descriptive Analysis The case number and ASR of incidence, prevalence and DALYs of CD among women of reproductive age in 1990 and 2023 were demonstrated. This study employed the Estimated Annual Percentage Change (EAPC) to evaluate trends in ASIR, ASPR, and ASDR. EAPCs were derived from a regression model (Y=α+βX+e) applied to ASR over time.21 The EAPC formula is expressed as 100×[exp(β)–1]. A linear regression model was used to compute the 95% confidence interval (CI) for EAPC.22 If both the EAPC and its 95% CI lower limit are positive, ASR exhibits an upward trend; if both the EAPC and its 95% CI upper limit are negative, ASR shows a downward trend; otherwise, ASR remains stable. Joinpoint Analysis Joinpoint regression is a widely used statistical approach for analyzing temporal trends in time-series data.23 It is particularly effective at identifying inflection points at which the trajectory of a disease burden undergoes a significant change. By detecting these joinpoints, the method enables evaluation of how policy changes, public health interventions, or social transitions may shape disease trends over time. In this study, trend analyses were performed using age-standardized rates (ASRs) from the GBD 2023 database, including the age-standardized prevalence rate (ASPR), age-standardized incidence rate (ASIR), and age-standardized DALY rate (ASDR) for CD. We employed Joinpoint software (Version 5.4.0.0; National Cancer Institute) to detect significant joinpoints and divide the time series into distinct segments. For each segment, we fitted log-linear regression models and computed the annual percent change (APC) to characterize trend magnitude and direction. The maximum number of joinpoints was set to 5, and model selection was based on permutation tests. To summarize the overall trend across the entire study period, we calculated the average annual percent change (AAPC), which represents a weighted average of segment-specific APC values.23 An upward trend was indicated by a positive APC/AAPC and corresponding 95% CI, while a downward trend was indicated by a negative APC/AAPC and corresponding 95% CI. Decomposition Analysis The Das Gupta decomposition method is an epidemiological way of pinpointing factors causing temporal variations in the burden of disease.24 It decomposes temporal fluctuations in DALYs and incident cases into three main components, namely population aging, population expansion and epidemiological shifts. Population expansion means changes in total population size that exert an influence on disease burden. For example, the accelerated growth of the population is likely to increase the overall burden of disease, though incidence and DALY rates are stable. Population aging depicts the trend whereby an increasing number of old people could elevate the burden of chronic and non-infectious diseases. Epidemiological shifts refer to variations in disease incidence or death rates, which reflect progress in public health interventions and medical care. Predictive Analysis We performed Bayesian Age-Period-Cohort (BAPC) analysis to project future trends in the incidence and DALY burden of CD among women aged 15–49 years. The BAPC model quantifies age, period, and cohort effects simultaneously. To ensure smooth and stable estimation, second-order random walk (RW2) priors were specified for age, period, and cohort effects.25 This model incorporates data from 1990 to 2023, considering the effects of age, time, and birth cohort. It employs integrated nested Laplace approximation to forecast trends from 2024 to 2040, enabling complete Bayesian inference.26 Model convergence and stability of effect estimates were assessed to validate model reliability. Key features of the BAPC model include: (1) the generation of age-specific and age-standardized predicted rates; and (2) the automatic addition of Poisson noise when the predicted distribution is of interest.27 To ensure smoothing, BAPC models assume independent mean-zero normal distributions on the second differences of all effects. Model convergence was assessed via posterior summaries of precision hyperparameters, with all effects showing narrow 95% credible intervals (CI), confirming adequate convergence and stability. Additionally, the progressive widening of prediction intervals over the projection horizon reflects appropriate uncertainty propagation inherent to the BAPC framework, consistent with established methods.25 All modeling procedures were conducted using the BAPC and INLA packages in R (version 4.5.1), and the projection horizon extended to 2040. Results Burden and Trend Changes of CD in India, China, the US and Worldwide from 1990 to 2023 The ASIRs, ASPRs, ASDRs and EAPCs of women of reproductive age with CD in the top three populous countries of the world from 1990 to 2023 are summarized in Table 1. In 2023, the ASIR in the US was highest at 9.44/100,000, while that in China was lowest at 0.70/100,000. Between 1990 and 2023, China showed the most pronounced increase in ASIR with an EAPC of 2.89 (95% CI: 2.23–3.55). On the whole, the incidence rate in China rose continuously from 0.29/100,000 in 1990 to approximately 0.9/100,000 during the plateau phase of 2013–2015, followed by a decrease to 0.70/100,000 in 2023. Incidence in the US grew modestly overall (EAPC: 0.41; 95% CI: 0.22–0.61); its rate rose from 8.83/100,000 in 1990 to a peak of 10.05/100,000 in 2007, then demonstrated a slow downward trend and reached 9.44/100,000 in 2023. Similarly, India demonstrated a modest overall increase (EAPC: 0.99; 95% CI: 0.79–1.18), characterized by a gradual elevation from 1.40/100,000 in 1990 to a 2015 peak of 1.89/100,000, eventually tapering to 1.73/100,000 in 2023. The global incidence rate rose first and then fell during the period over the observation period. The trend of ASPR varied significantly. In 2023, the ASPR in the US remained the highest at 83.26/100,000, but it was 5.47/100,000 in China. During the period from 1990 to 2023, China also showed the fastest rise in ASPR, with an EAPC of 2.51 (95% CI: 1.77–3.26); India exhibited a marked increase in ASPR, with an EAPC of 1.03 (95% CI: 0.80–1.26). Globally, the ASPR showed a slight downward trend, with an EAPC of −0.21 (95% CI: −0.43–0.02); the ASPR in the US demonstrated little growth, with an EAPC of 0.01 (95% CI: −0.22–0.25). As for ASDR, it was highest at 18.35/100,000 in the US in 2023 and 3.93/100,000 in India. During the period from 1990 to 2023, India presented the most marked downward trend in ASDR, with an EAPC of −0.36 (95% CI: −0.47–-0.24); China showed a slight increase in ASDR, with an EAPC of 0.13 (95% CI: −0.38–0.65); the US remained relatively stable in ASDR, with an EAPC of −0.04 (95% CI: −0.21–0.13). As a whole, the burden of CD among women of reproductive age in these regions showed significant heterogeneity between 1990 and 2023 (Table 1 and Figure 1, Supplement Table 1).Table 1The Number of Incident Cases, Age-Standardized Incidence Rate (ASIR), Disability-Adjusted Life years (DALYs), Age-Standardized DALYs Rate, Number of Prevalence and Age-Standardized Prevalence Rate (ASPR) of Crohn’s Disease (CD)LocationMeasure19902023NumberAge-Standardized Rates per 100000 PeopleNumberAge-Standardized Rates per 100000 People1990–2023 EAPCn (95% UI)n (95% UI)n (95% UI)n (95% UI)n (95% CI)GlobalIncidence24503 (19,520–30,842)1.83 (1.46–2.30)37,982 (29,524–49,408)1.93 (1.50–2.50)0.20 (0.04, 0.36)Prevalence254664 (201,546–323,124)19.01 (15.05–24.12)354,268 (268,031–450,567)17.96 (13.59–22.84)−0.21 (−0.43, 0.02)DALYs72528 (53,916–94,911)5.41 (4.03–7.09)98,906 (71,241–134,084)5.01 (3.61–6.80)−0.35(−0.44, -0.26)IndiaIncidence2837 (2196–3669)1.40 (1.09–1.82)6696 (5194–8674)1.73 (1.34–2.24)0.99 (0.79, 1.18)Prevalence22097 (16,963. - 30,015)10.94 (8.40–14.86)55,726 (41,908–75,434)14.40 (10.83–19.49)1.03 (0.80, 1.26)DALYs8708 (4718–14,651)4.31 (2.34–7.26)15,222 (9870–22,013)3.93 (2.55–5.69)−0.36(−0.47, -0.24)ChinaIncidence943 (699–1322)0.29 (0.22–0.41)2175 (1662–2896)0.70 (0.54–0.94)2.89 (2.23, 3.55)Prevalence8285 (6070–11,562)2.56 (1.88–3.58)16,874 (12,638–21,973)5.47 (4.10–7.12)2.51 (1.77, 3.26)DALYs3451 (1980–5845)1.07 (0.61–1.81)3434 (2296–4811)1.11 (0.74–1.56)0.13 (−0.38, 0.65)United States of AmericaIncidence5917 (4560–7602)8.83 (6.81–11.34)7158 (5524–9069)9.44 (7.29–11.96)0.41 (0.22, 0.61)Prevalence56792 (42,841–73,969)84.75 (63.93–110.38)63,122 (48,018–81,946)83.26 (63.34–108.09)0.01 (−0.22, 0.25)DALYs12082 (8284–16,399)18.03 (12.36–24.47)13,910 (10,044–19,045)18.35 (13.25–25.12)−0.04 (−0.21, 0.13) Figure 1The changing trends of the incidence rate (per 100,000 people) of Crohn’s disease among women of reproductive age globally, in the United States, China and India from 1990 to 2023.The image contains four line graphs depicting the incidence trends of Crohn's disease among women from 1990 to 2023. The first graph, labeled 'Global', shows the incidence rate on the y-axis and year on the x-axis, with a peak around 2010. The second graph, labeled 'China', shows a similar trend with a peak around 2013-2015 and a decline afterward. The third graph, labeled 'India', indicates a gradual increase peaking around 2015, followed by a slight decline. The fourth graph, labeled 'United States of America', shows a peak around 2007, followed by a decrease and stabilization. Each graph represents the incidence rate for females over the specified period.Graphs of Crohn's disease trends in women: global, China, India, USA (1990-2023). Table 1The Number of Incident Cases, Age-Standardized Incidence Rate (ASIR), Disability-Adjusted Life years (DALYs), Age-Standardized DALYs Rate, Number of Prevalence and Age-Standardized Prevalence Rate (ASPR) of Crohn’s Disease (CD)LocationMeasure19902023NumberAge-Standardized Rates per 100000 PeopleNumberAge-Standardized Rates per 100000 People1990–2023 EAPCn (95% UI)n (95% UI)n (95% UI)n (95% UI)n (95% CI)GlobalIncidence24503 (19,520–30,842)1.83 (1.46–2.30)37,982 (29,524–49,408)1.93 (1.50–2.50)0.20 (0.04, 0.36)Prevalence254664 (201,546–323,124)19.01 (15.05–24.12)354,268 (268,031–450,567)17.96 (13.59–22.84)−0.21 (−0.43, 0.02)DALYs72528 (53,916–94,911)5.41 (4.03–7.09)98,906 (71,241–134,084)5.01 (3.61–6.80)−0.35(−0.44, -0.26)IndiaIncidence2837 (2196–3669)1.40 (1.09–1.82)6696 (5194–8674)1.73 (1.34–2.24)0.99 (0.79, 1.18)Prevalence22097 (16,963. - 30,015)10.94 (8.40–14.86)55,726 (41,908–75,434)14.40 (10.83–19.49)1.03 (0.80, 1.26)DALYs8708 (4718–14,651)4.31 (2.34–7.26)15,222 (9870–22,013)3.93 (2.55–5.69)−0.36(−0.47, -0.24)ChinaIncidence943 (699–1322)0.29 (0.22–0.41)2175 (1662–2896)0.70 (0.54–0.94)2.89 (2.23, 3.55)Prevalence8285 (6070–11,562)2.56 (1.88–3.58)16,874 (12,638–21,973)5.47 (4.10–7.12)2.51 (1.77, 3.26)DALYs3451 (1980–5845)1.07 (0.61–1.81)3434 (2296–4811)1.11 (0.74–1.56)0.13 (−0.38, 0.65)United States of AmericaIncidence5917 (4560–7602)8.83 (6.81–11.34)7158 (5524–9069)9.44 (7.29–11.96)0.41 (0.22, 0.61)Prevalence56792 (42,841–73,969)84.75 (63.93–110.38)63,122 (48,018–81,946)83.26 (63.34–108.09)0.01 (−0.22, 0.25)DALYs12082 (8284–16,399)18.03 (12.36–24.47)13,910 (10,044–19,045)18.35 (13.25–25.12)−0.04 (−0.21, 0.13) The Number of Incident Cases, Age-Standardized Incidence Rate (ASIR), Disability-Adjusted Life years (DALYs), Age-Standardized DALYs Rate, Number of Prevalence and Age-Standardized Prevalence Rate (ASPR) of Crohn’s Disease (CD) The changing trends of the incidence rate (per 100,000 people) of Crohn’s disease among women of reproductive age globally, in the United States, China and India from 1990 to 2023. Age-Specific Pattern Analysis In 2023, the peak incidence of CD among women of reproductive age occurred predominantly in the age group of 35–44. China had a significantly lower number of cases in every age group than the US and the world. The peak incidence of women of reproductive age in China occurred at the age of 35–39, while that in the US, India and globally occurred at the age of 40–44 (Figure 2A and Supplement Table 2). The proportion of cases in the US, India and globally was centered around older age groups. The 45–49 age group in the US (25.4%) and India (22.2%), and the 15–19 age group had the lowest proportion. The age composition in China differed structurally. Specifically, the age group of 35–39 had the highest proportion of cases (21.9%), and that of 15–19 had a slightly greater proportion of cases (3.9%) than the lowest age groups in India, the US and globally (Figure 2B and Supplement Table 2). Figure 2(A) The age-specific proportion of incident Crohn’s disease cases among women of reproductive age in the United States, India, China, and globally in 2023. (B) The age-specific proportion of prevalent Crohn’s disease cases among women of reproductive age in the United States, India, China, and globally in 2023.The bar charts illustrate age-specific proportions of Crohn’s disease cases among women of reproductive age in 2023 across the USA, India, China and globally. For incident cases, the USA shows the highest proportion in the 40–44 age group (20.8%), while India peaks at20.1% in the same group. China has its highest at 21.9% for ages 35–39 and globally, the peak is 18.8% for 35–39 years. For prevalent cases, the USA peaks at 25.4% for ages 45–49, India at 22.2% for the same group, China at 21.9% for 35–39 years and globally, the highest is 21.5% for 45–49 years. Each region shows a decline in proportions as age increases, with the lowest proportions in the 15–19 age group across all regions.Bar charts of age-specific Crohn's disease cases in women: US, India, China, globally. (A) The age-specific proportion of incident Crohn’s disease cases among women of reproductive age in the United States, India, China, and globally in 2023. (B) The age-specific proportion of prevalent Crohn’s disease cases among women of reproductive age in the United States, India, China, and globally in 2023. From 1990 to 2023, the 45–49 age group consistently maintained the highest incidence and prevalence rates across all regions, while the 15–19 age group consistently recorded the lowest. Across all cohorts, the US reported incidence and prevalence rates substantially higher than the global average, China, and India. In China, all age groups demonstrated a steady upward trend in both incidence and prevalence; notably, the 30–34 age group exhibited the most substantial absolute growth during the observation period (Figure 3A and B, Supplement Table 3). Figure 3(A) The age-specific composition ratio of the incidence number of Crohn’s disease among women of reproductive age in the United States, India, China and globally in 2023. (B) The age-specific composition ratio of the standardized prevalence rate of Crohn’s disease among women of reproductive age in the United States, India, China and globally in 2023.Image A presents line graphs of Crohn's disease incidence from 1990 to 2023 in Global, India, China and USA. The x-axis is 'Year' and y-axis 'Incidence'. Age groups are 15-19, 20-24, 25-29, 30-34, 35-39, 40-44 and 45-49 years. The 45-49 group has the highest incidence, 15-19 the lowest. Image B shows prevalence graphs for the same regions and years, with similar age groups. Again, 45-49 years have the highest prevalence, 15-19 the lowest. USA reports higher rates than other regions. China shows a steady increase in both incidence and prevalence, notably in the 30-34 age group.Two graphs showing incidence and prevalence of Crohn's disease by age group from 1990 to 2023 in four regions. (A) The age-specific composition ratio of the incidence number of Crohn’s disease among women of reproductive age in the United States, India, China and globally in 2023. (B) The age-specific composition ratio of the standardized prevalence rate of Crohn’s disease among women of reproductive age in the United States, India, China and globally in 2023. Joinpoint Regression Analysis China and India had higher AAPCs of ASIR than the US. Specifically, the AAPC was 2.75 (95% CI: 2.63 to 2.88) in China, 0.63 (95% CI: 0.61 to 0.65) in India and 0.23 (95% CI: 0.20 to 0.26) in the US (Figure 4A and Supplement Table 4). China and India had higher AAPCs of ASPR than the US and the globe. Concretely, the AAPC was 2.39 (95% CI: 2.27 to 2.51) in China, 0.82 (95% CI: 0.78 to 0.86) in India, −0.04 (95% CI: −0.08 to −0.001) in the US and −0.16 (95% CI: −0.20 to −0.12) globally (Figure 4B and Supplement Table 4). Regarding the AAPCs of ASDR, China and the US showed mild upward trends, while India and the globe exhibited downward trends. Specifically, the AAPC was 0.17 (95% CI: 0.10 to 2.54) in China, −0.29 (95% CI: −0.35 to −0.24) in India, 0.06 (95% CI: −0.01 to 0.12) in the US and −0.23 (95% CI: −0.26 to −0.20) globally (Figure 4C and Supplement Table 4). Figure 4Annual percent change (APC) and trends of Crohn’s disease among women of reproductive age in India, China, the United States and globally from 1990 to 2023. (A) Incidence rate. (B) Prevalence rate. (C) DALYs rate.Image A: Line graph of Crohn’s disease incidence rate change (1990-2023). X-axis: Year, Y-axis: Annual Percent Change. China shows an increase, peaking in 2010. India trends slightly upward, while the US and global rates are stable. Image B: Line graph of Crohn’s disease prevalence rate change (1990-2023). X-axis: Year, Y-axis: Annual Percent Change. China and India show upward trends, with China peaking in 2010. The US shows a slight decline and the global trend is stable. Image C: Line graph of Crohn’s disease DALYs rate change (1990-2023). X-axis: Year, Y-axis: Annual Percent Change. China shows a mild upward trend, peaking in 2010. India and global trends decline, while the US remains stable.Three line graphs showing trends of Crohn’s disease rates from 1990 to 2023 in India, China, the US and globally. Annual percent change (APC) and trends of Crohn’s disease among women of reproductive age in India, China, the United States and globally from 1990 to 2023. (A) Incidence rate. (B) Prevalence rate. (C) DALYs rate. Decomposition Analysis The incidence rate of CD among women of reproductive age in China is −36.26% affected by aging, 43.58% affected by population, and 92.68% affected by epidemiological change. The incidence rate in India is 43.15% affected by aging, 40.78% affected by population, and 16.07% affected by epidemiological change. The incidence rate in the United States is −118.18% affected by aging, 185.87% affected by population, and 32.31% affected by epidemiological change. The incidence rate globally is 23.43% affected by aging, 79.83% affected by population, and −3.26% affected by epidemiological change (Figure 5A and Supplemental Table 5). Figure 5Decomposition analysis results of Crohn’s disease in women of reproductive age. (A) ASIR, (B) ASDR.Image A presents a bar graph of Crohn's disease incidence in the USA, India, Global and China. The x-axis is 'Incidence' and the y-axis lists regions. Bars are segmented into aging, epidemiological change and population. Aging negatively affects incidence in the USA and China but positively in India and globally. Population yields positive contributions across all regions. Epidemiological change drives incidence upward in the three countries but downward globally. Image B displays a bar graph of Disability-Adjusted Life Years (DALYs) for Crohn's disease in the same regions. The x-axis is 'DALYs' and the y-axis lists regions. Bars are similarly divided. Aging negatively impacts DALYs in the USA, but contributes positively in China, India, and globally. Population expansion shows a negative contribution to DALYs uniquely in China, while contributing positively in the other regions. Epidemiological change exerts a negative contribution globally, in India, and in the USA, but acts as a positive driver in China.Bar graphs: Crohn's disease incidence and DALYs by age, epidemiology and population in four regions. Decomposition analysis results of Crohn’s disease in women of reproductive age. (A) ASIR, (B) ASDR. The DALY rate of CD among women of reproductive age globally is 35.87% affected by aging, 113.84% affected by population, and −49.71% affected by epidemiological change. The DALY rate in China is 6215.90% affected by aging, −7430.61% affected by population, and 1314.71% affected by epidemiological change. The DALY rate in the United States is −146.06% affected by aging, 251.08% affected by population, and −5.02% affected by epidemiological change. The DALY rate in India is 65.82% affected by aging, 63.15% affected by population, and −28.97% affected by epidemiological change (Figure 5B and Supplemental Table 5). BAPC Prediction In China, the ASIR is projected to increase modestly and reach 0.74/100,000 by 2040. Correspondingly, the ASDR is expected to be 0.91/100,000 in the same year. In India, the ASIR is anticipated to maintain a continuous declining trend, with a projected value of 1.76/100,000 by 2040. Similarly, the ASDR is forecast to decrease and drop to 3.05/100,000 by 2040. As regards the US, model predictions indicate that the ASIR will continue its downward trend and decline to 7.55/100,000 by 2040. Concurrently, the ASDR is also expected to decrease and reach 14.22/100,000 by 2040 (Figures 6 and 7, Supplement Tables 6 and 7). Figure 6Trends in age-standardized incidence rates of Crohn’s disease among women of reproductive age from 1990 to 2040 predicted by the BAPC model. The grey solid line shows the observed and forecasted mean ASR per 100,000 population. The red dotted line indicates the projected trend from 2025 to 2040. The shaded purple regions represent uncertainty intervals: the darker inner band corresponds to the 50% uncertainty interval, and the lighter outer band corresponds to the 95% uncertainty interval. (A) Incidence in Global. (B) Incidence in India. (C) Incidence in China. (D) Incidence in USA.The image A shows a graph for the Globe with the x-axis labeled 'Year' and the y-axis labeled from 1.25 to 2.25. The graph shows a fluctuating trend from 1990 to 2025, followed by a projected decline with uncertainty intervals until 2040. The image B shows a graph for India with similar axes. The trend rises until around 2015, then stabilizes and projects a slight decline. The image C shows a graph for China with the y-axis ranging from 0.25 to 1.25. The trend rises until 2015, then stabilizes with a slight projected increase. The image D shows a graph for the United States of America with the y-axis ranging from 6 to 11. The trend peaks around 2007 then declines with a projected downward trend. Each graph includes a red dotted line indicating future projections and shaded areas representing uncertainty intervals.Four graphs showing Crohn’s disease incidence trends from 1990 to 2040 for Globe, India, China and USA. Figure 7Trends in age-standardized DALY rates of Crohn’s disease among women of reproductive age from 1990 to 2040 predicted by the BAPC model. The grey solid line shows the observed and predicted mean DALY rate per 100,000 population. The red dotted line indicates the projected trend from 2025 to 2040. The shaded purple regions represent uncertainty intervals: the darker inner band corresponds to the 50% uncertainty interval, and the lighter outer band corresponds to the 95% uncertainty interval. (A) DALYs in Global. (B) DALYs in India. (C) DALYs in China. (D) DALYs in USA.The image A shows a graph titled 'Globe' with the x-axis labeled 'Year' and the y-axis labeled with values from 3.5 to 5.5. The graph shows a declining trend from 1990 to 2020, with a projected trend from 2025 to 2040 indicated by a red dotted line and shaded uncertainty intervals. The image B shows a graph titled ‘India’ with axes (ranging from 2.5 to 4.5). It shows a decline from 1990 to 2020, with projections from 2025 to 2040. The image C shows a graph titled 'China' with the y-axis ranging from 0.5 to 1.75, depicting fluctuations from 1990 to 2020 and projections from 2025 to 2040. The image D shows a graph titled 'United States of America' with the y-axis ranging from 12.5 to 20.0, showing fluctuations from 1990 to 2020 and projections from 2025 to 2040. Each graph includes shaded regions representing uncertainty intervals.Four graphs showing DALY trends for Crohn's disease from 1990 to 2040 in Globe, India, China and USA. Trends in age-standardized incidence rates of Crohn’s disease among women of reproductive age from 1990 to 2040 predicted by the BAPC model. The grey solid line shows the observed and forecasted mean ASR per 100,000 population. The red dotted line indicates the projected trend from 2025 to 2040. The shaded purple regions represent uncertainty intervals: the darker inner band corresponds to the 50% uncertainty interval, and the lighter outer band corresponds to the 95% uncertainty interval. (A) Incidence in Global. (B) Incidence in India. (C) Incidence in China. (D) Incidence in USA. Trends in age-standardized DALY rates of Crohn’s disease among women of reproductive age from 1990 to 2040 predicted by the BAPC model. The grey solid line shows the observed and predicted mean DALY rate per 100,000 population. The red dotted line indicates the projected trend from 2025 to 2040. The shaded purple regions represent uncertainty intervals: the darker inner band corresponds to the 50% uncertainty interval, and the lighter outer band corresponds to the 95% uncertainty interval. (A) DALYs in Global. (B) DALYs in India. (C) DALYs in China. (D) DALYs in USA. Discussion The current study indicates that the CD burden in women of reproductive ages varies greatly depending on the region and age of the female population in India, China and the United States. Even though previous GBD-based studies have thoroughly depicted the overall picture of global IBD trends, our research integrates the idea of epidemiological transitions into maternal health by singling out this particular, and medically weak, group of people in three archetypes of economy. While the history of CD has traditionally been described as a disease of people in high income countries, our results indicate a changing epidemiology. The rates remain high in high-income settings, such as the US, but they are now leveling off or decreasing slightly. Conversely, the incidence in fast-growing economies, such as China, is growing rapidly off a low historical background. This worldwide divide in CD occurrence is likely to be closely linked to socioeconomic shifts as well as changing environmental exposure. In literature, there is a lot of literature concerning the risk factors of CD development including smoking and mental stress, adoption of the so-called Western dietary practices, and taking oral contraceptives or non-steroidal anti-inflammatories.28,29 In our study population, exposure to such factors during pregnancy is especially crucial since they might impact a child’s risk, and the postpartum period is also a highly vulnerable stage that can cause the exacerbation of diseases. Recent modernization of China especially, switching over to Western type of foods and novel environmental exposures are expected to be the main triggers of fast increase in CD incidence.30,31 Besides, access to high quality diagnostic instruments has greatly lowered the levels of past underdiagnosis.32 Although the total number of cases grows, DALY reduction points to the success of medical treatment strategies. Introduction of biological drugs (antitumor necrosis factor (TNF) therapy), and advanced monitoring devices (endoscopy and molecular testing) have been playing a crucial role. These interventions have helped reduce the extent of disability and mortality rates through ensuring early detection and elimination of strictures, fistulas and other severe complications that make health loss less significant.33–35 Our decomposition analysis further mathematically isolates the drivers behind these regional trajectories. The main driving forces of the incidence change in China were epidemiological factors, which contributed to almost 93% of the variance. It is reasonable to have such a high percentage considering the historically low disease baseline in China. Interestingly, both decomposition percentages of China’s DALY burden seem excessive (e.g., 6215.90 for aging, −7430.61 for population) which is a mathematical artifact resulting in the fact that China had an exceedingly low baseline DALY rate (1.07/100,000 in 1990). Small absolute variations, when compared to this almost zero denominator, will provide very high percentages. However, the directional interpretation still holds: epidemiological change as the main cause in China compared to demographic factors in India and the United States. Recent decades witnessed an explosive increase in incidence rates due to rapid life change and better diagnosis instruments, the rate of which is much faster than the slow influence of demographic factors, a trend that matches the accelerated epidemiological shift from a low-disease baseline in China. In India, however, the burden also pushed in a somewhat more symmetrical way as a result of population growth and demographic aging. Population growth was mainly an indicator of increasing case numbers in the US, finally counterbalancing the real decline in epidemiological risk profile. These background factors may be explained by disparate socioeconomic environments and environmental exposure histories, ie, fast urbanization changing the initial experience of the immune system or the integrity of the gut microbiome.36,37 Nevertheless, such mechanistic hypotheses necessarily need to be tested longitudinally using individual-level cohorts. Specific age stratification brought other important observations. Women of reproductive age in China experienced the highest rate of CD earlier (35–39) compared to American women and Indian women (40–44). Such an article early peak in the Chinese group is a unique clinical problem because the peak of the disease coincides exactly with the optimal childbearing age. The younger population may be explained by the birth cohort phenomenon, whereby younger populations within the fast-industrializing countries are exposed to westernized risk factors at an earlier age than their older counterparts.38,39 In contrast, the delayed peak in the US is characteristic of prevalence accumulation within a mature epidemiological landscape. It is interesting to note that there is an anomaly in the joinpoint analysis, which shows a clear resumption in the disease burden indicators starting in 2020 and ending in 2023. There is a need to exercise caution when interpreting the synchronous global increase in incidence and prevalence as well as DALYs during the COVID-19 pandemic. It can be driven by the rebound effect due to pandemic-related diagnostic delays,40 stress-mediated disease flares,41 or the postulated immune dysfunction due to viral infection.42 Regardless of the particular cause, such volatility highlights the need to have robust gastroenterological care systems that can be resilient to system disruptions. From a public health perspective, the convergence of CD incidence with reproductive years in emerging economies necessitates multidisciplinary care models integrating gastroenterologists, obstetricians, and clinical dietitians. Clear communication about the safety of biologics during pregnancy is also essential. This helps prevent patients from unnecessarily stopping their medication and risking a relapse. Strategies should remain regionally tailored: high-income systems should prioritize long-term complication management, whereas emerging economies would benefit from focusing on early detection and the mitigation of modifiable environmental risks. This study is constrained by several limitations inherent to ecological analyses utilizing GBD 2023 data. Firstly, the quality of data and representativeness are different. GBD estimates for some regions (especially rural or remote areas in India and China) are dependent on trend extrapolation and predictive covariates. Bias may be introduced by the misdiagnosis and underdiagnosis of CD in women of reproductive age. Due to insufficient clinical data at the individual level (such as disease activity, pregnancy history and oral contraceptive use), the associations of these specific factors with the burden of CD were not further analyzed. Secondly, this study cannot confirm causalities between epidemiological factors, demographic shifts and CD onset. In the meantime, the dose-response impact of risk factors was not explored, as causal inference at the individual level was precluded by the ecological design of the present study. Thirdly, the decomposition analysis was grounded in statistical model assumptions. Parameter settings (eg, confounder adjustments) may have an impact on the results. The model failed to incorporate the regulatory effect of physiological factors specific to women of reproductive age (eg, hormonal fluctuations) on the progression of CD. Finally, the construction of prediction models was on the basis of historical trends. It did not fully take into account the potential influence of future uncertainties like public health emergencies and medical policy shifts (for instance, biologics are widely accessible). There is a pressing need for future investigations to prioritize prospective, individual-level longitudinal studies to elucidate the biological mechanisms driving these regional disparities, particularly the interplay among urbanization, hormonal fluctuations, and the microbiome. Clinical research should systematically evaluate real-world maternal and fetal outcomes under multidisciplinary CD management. Ultimately, cross-national cohorts will be essential to untangle the relative contributions of genetic susceptibility and environmental shifts in defining these distinct disease trajectories. Conclusion In summary, our descriptive analysis highlights distinct regional and age-specific patterns in the CD burden among women of reproductive age. Rather than a uniform global trend, we observed contrasting disease trajectories that align closely with different stages of socioeconomic development. In emerging economies like China, the rapid acceleration in incidence and the earlier age of onset (ages 30–39) suggest a practical need for heightened clinical awareness during prime childbearing years. Multidisciplinary care models might be especially useful in balancing disease management and reproductive health requirements in these types of conditions. India, where changes in demographic factors are the cause of growth in the number of cases, has improved medical services capacity as its first priority. Conversely, for high-income nations such as the United States, stabilizing incidence rates suggest that healthcare systems may need to focus more on managing long-term complications as patient populations age. Overall, our findings indicate that CD management strategies cannot be uniformly applied across the globe. Future clinical and public health planning would benefit from being tailored to the specific demographic and epidemiological profiles of each region.